TriangleNCT00917384 · CITED IN SOURCE DOCUMENTS
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2019-09-25
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Overall Survival (OS)
Progression-Free Survival (PFS)
Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate)
Percentage of Participants With Objective Response (Objective Response Rate [ORR])
Duration of Response (DOR)
Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30)
Number of Participants With Adverse Events
Maximum Concentration (Cmax) of IMC-1121B
Number of Participants Who Developed Antibodies Against IMC-1121B
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histologically or cytologically confirmed gastric carcinoma, including gastric adenocarcinoma or GEJ adenocarcinoma * Metastatic disease or locally recurrent, unresectable disease with measurable lymph node metastases * Measurable disease and/or evaluable disease. Measurable disease is defined as at least one unidimensionally-measurable target lesion \[≥ 2 centimeter (cm) with conventional techniques or ≥ 1 cm by spiral computed tomography (CT)\], as defined by Response using Response Evaluation Criteria in Solid Tumors (RECIST). Examples of evaluable, nonmeasurable disease include gastric, peritoneal, or mesenteric thickening in areas of known disease, or peritoneal nodules that are too small to be considered measurable by RECIST * Experienced disease progression during or within 4 months after the last dose of first-line therapy for metastatic disease, or during or within 6 months after the last dose of adjuvant therapy * Disease is not amenable to potentially curative resection * Participant is ≥ 18 years of age * Participant has a life expectancy of ≥ 12 weeks * Participant resolution to Grade ≤ 1 (or to Grade ≤ 2 in the case of neuropathy) by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (with the exception of alopecia) * Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-1 * The participant has adequate hepatic function as defined by a total bilirubin ≤ 1.5 milligrams/deciliter (mg/dL) \[25.65 micromole/liter (µmol/L)\], and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x the upper limit of normal (ULN) \[or 5.0 x the ULN in the setting of liver metastases\] * The participant has adequate renal function as defined by a serum creatinine ≤ 1.5 x the ULN, or creatinine clearance (measured via 24-hour urine collection) ≥ 40 milliliters/minute (mL/min) (that is, if serum creatinine is \> 1.5 x the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) * The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (\[UA\]; if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine collection for protein must demonstrate \< 1000 milligrams (mg) of protein in 24 hours to allow participation in the study) * The participant has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) ≥ 1000 microliters (µL), hemoglobin ≥ 9 grams/deciliter (g/dL) \[5.58 millimoles/liter (mmol/L)\], and platelets ≥ 100,000/µL * The participant must have adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy). Participant on anticoagulation therapy with unresected primary tumors or local tumor recurrence following resection are not eligible * If the participant has received prior anthracycline therapy as part of his or her first-line regimen, the participant is able to engage in ordinary physical activity without significant fatigue or dyspnea * Because the teratogenicity of IMC-1121B is not known, the participant, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods) * Female participant of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization * Able to provide informed written consent and is amenable to compliance with protocol schedules and testing Exclusion Criteria: * Documented and/or symptomatic brain or leptomeningeal metastases * Experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to randomization * Experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to randomization * Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator * Ongoing or active psychiatric illness or social situation that would limit compliance with study requirements * Uncontrolled or poorly-controlled hypertension despite standard medical management * Participant has a serious or nonhealing wound, ulcer, or bone fracture * Received chemotherapy, radiotherapy, immunotherapy, or targeted therapy for gastric cancer within 2 weeks prior to randomization * Received any investigational therapy within 30 days prior to randomization * Undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization * Received prior therapy with an agent that directly inhibits vascular endothelial growth factor (VEGF) or VEGF receptor 2 (R-2) activity (including bevacizumab), or any antiangiogenic agent * Receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use \[maximum dose 325 milligram/day (mg/day)\] is permitted * Participant has elective or planned major surgery to be performed during the course of the clinical trial * Participant has a known allergy to any of the treatment components * Pregnant or lactating * Known to be positive for infection with the human immunodeficiency virus * Known alcohol or drug dependency * Participant has a concurrent active malignancy other than adequately-treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that he/she has been free of disease for \> 3 years
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
- intervention Names
- Biological: ramucirumab
- Other: Best Supportive Care (BSC)
- label
- ramucirumab
- type
- EXPERIMENTAL
- description
- Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
- intervention Names
- Drug: Placebo
- Other: Best Supportive Care (BSC)
- label
- Placebo
- type
- PLACEBO_COMPARATOR
- interventions
- arm Group Labels
- ramucirumab
- description
- Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
- name
- ramucirumab
- other Names
- IMC-1121B
- LY3009806
- type
- BIOLOGICAL
- arm Group Labels
- Placebo
- description
- Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
- name
- Placebo
- type
- DRUG
- arm Group Labels
- Placebo
- ramucirumab
- description
- BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
- name
- Best Supportive Care (BSC)
- type
- OTHER
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- QUADRUPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 355
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Overall survival is defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the date of data cut-off or who were lost to follow-up were censored on the last date the participant was known to be alive
- measure
- Overall Survival (OS)
- time Frame
- Randomization up to 28 months post-randomization
- secondary Outcomes
- description
- PFS is defined as the time from date of randomization until date of objectively determined progressive disease (PD) or death due to any cause, whichever is first. Participants alive and without PD were censored at the time of last adequate objective tumor assessment (that is, response other than unevaluable).
- measure
- Progression-Free Survival (PFS)
- time Frame
- Randomization up to 17 months
- description
- The percentage of participants alive and progression-free 12 weeks after randomization. Progression-free survival (PFS) is defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) or death due to any cause whichever comes first. Participants alive and without PD were censored at the time of the last adequate objective tumor assessment.
- measure
- Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate)
- time Frame
- Week 12 post-randomization
- description
- ORR is equal to the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR). CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment.
- measure
- Percentage of Participants With Objective Response (Objective Response Rate [ORR])
- time Frame
- Randomization up to 17 months post-randomization
- description
- DOR is the interval from date of initial documented response (complete response \[CR\] or partial response \[PR\]) to first documented date of disease progression (PD) or death as a result of any cause. CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment. Participants who did not relapse or die were censored at the time of the last adequate objective tumor assessment.
- measure
- Duration of Response (DOR)
- time Frame
- Randomization up to 17 months post-randomization
- description
- EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. Best change from baseline results determined by Least Square (LS) mean estimated with randomization stratification factors and baseline value as continuous covariate.
- measure
- Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30)
- time Frame
- Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])
- description
- Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and all other NSAEs is located in the Reported Adverse Event module.
- measure
- Number of Participants With Adverse Events
- time Frame
- Randomization up to 18 months
- description
- Cmax was not analyzed as only pre-dose samples were collected.
- measure
- Maximum Concentration (Cmax) of IMC-1121B
- time Frame
- 6 weeks post-randomization
- description
- The number of participants who developed treatment emergent antibody responses to IMC-1121B after baseline.
- measure
- Number of Participants Who Developed Antibodies Against IMC-1121B
- time Frame
- Baseline, 12 Weeks
Full study description
- brief Summary
- The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- detailed Description
- Placebo-controlled, multicenter Phase 3 study of participants with metastatic gastric cancer \[including adenocarcinomas of the gastroesophageal junction (GEJ)\] and disease progression on standard first-line chemotherapeutic regimens. Participants will be randomized on a 2:1 basis to receive best supportive care plus ramucirumab administered every 2 weeks or best supportive care plus placebo administered every 2 weeks, respectively. Participants will undergo radiographic assessment of disease status every 6 weeks. Participant will be treated until there is evidence of progressive disease, toxicity requiring cessation, withdrawal of consent, or until other withdrawal criteria are met. Approximately 348 participants, with histologically- or cytologically-confirmed, metastatic gastric or GEJ adenocarcinoma, and radiographically measurable disease as defined by the Response Evaluation Criteria in Solid Tumors or evaluable, nonmeasurable disease, will be randomized. Participants will be enrolled from approximately 250 study centers in North America, South America, Central America, Asia, Australia, New Zealand, and Europe.
Source references
- references
- citation
- Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.
- pmid
- 30557792
- type
- DERIVED
- citation
- Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.
- pmid
- 28716815
- type
- DERIVED
- citation
- Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.
- pmid
- 24094768
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-68a6a82baf6126373df2
- requested nct id
- NCT00917384
- primary nct id
- NCT00917384
- source kind
- fda_spl_label
- source record id
- 161cb5e7-7955-45e5-bdde-9be94fdbe76a
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- 931f0700cfe1dff700400720219808d8320dba97c8e94463337df30b73f7b691
- payload
- application numbers
- BLA125477
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-68a6a82baf6126373df2
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00917384
- occurrences
- context exact
- 14 CLINICAL STUDIES 14.1 Gastric Cancer REGARD The efficacy of CYRAMZA was evaluated in REGARD (NCT00917384), a multinational, randomized, double-blind, multicenter study in patients with locally advanced or metastatic gastric cancer (including adenocarcinoma of the
- end
- 107
- exact text
- NCT00917384
- start
- 96
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/72/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 161cb5e7-7955-45e5-bdde-9be94fdbe76a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 8b976ba12932042765823e0997b9bfba65f6d17d93c7789d351e39674335679f
- spl effective time
- 20260609
- spl set id
- c6080942-dee6-423e-b688-1272c2ae90d4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-9739dfa9ffe36251fff0
- requested nct id
- NCT00917384
- primary nct id
- NCT00917384
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 20f13c5c62ce6ffbb2dafce9a99993b62ee853964501fae15509a2830b8349c2
- payload sha256
- 4060728727d3f65052369dcd9dab337f317cd3f1177b42cb4ff2228bce4fcb7b
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-9739dfa9ffe36251fff0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00917384
- occurrences
- context exact
- idence (ramucirumab):</p> <div class="pdq-content-list"><ol id="_580"><li>The international, phase III, placebo-controlled, <a href="/clinicaltrials/NCT00917384">REGARD</a> trial (NCT00917384) included 355 patients with stage IV gastric or gastroesophageal junction cancer who had progressed on a first-line 5-FU‒
- end
- 130728
- exact text
- NCT00917384
- start
- 130717
- context exact
- <div class="pdq-content-list"><ol id="_580"><li>The international, phase III, placebo-controlled, <a href="/clinicaltrials/NCT00917384">REGARD</a> trial (NCT00917384) included 355 patients with stage IV gastric or gastroesophageal junction cancer who had progressed on a first-line 5-FU‒ or platinum-containing regimen.
- end
- 130759
- exact text
- NCT00917384
- start
- 130748
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/b520476df769e6fecd.html
- source file sha256
- 20f13c5c62ce6ffbb2dafce9a99993b62ee853964501fae15509a2830b8349c2
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:22:22.075850+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 93e6df01e9e806a0673bf0152a2eeeb828353c1de1fb5bdf86185aac466f15f4
- source title
- Gastric Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 21, 2025
- datetime
- 2025-02-21T12:00:00Z
- display
- February 21, 2025
Preserved source evidence · Not medical advice